Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Spillane

Showing results (221-230 of 223) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 223 results.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology|December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingRichard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Pageof 23

Showing results (221-230 of 223) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 223 results.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Pathology|December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingRichard A Scolyer, Victoria Atkinson, David E Gyorki, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Pageof 23